Fiche société
Voyager Therapeutics
Traitements, essais et publications liés.
Traitements5programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Anti-AAV9 Total Antibody (TAb) AssayVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| VY1706 High DoseVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| VY1706 Low doseVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| VY1706 Mid doseVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| VY1706 Low doseVY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| VY1706 Low dose | Alzheimer | Phase 1 | NCT07764146 | An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease | RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||